徳島大学病院は徳島県徳島市蔵本町にある、国立大学法人・徳島大学により運営される特定機能病院である。 徳島県立中央病院とは連絡ブリッジで接続されており、徳島市蔵本地区は徳島県における総合メディカルゾーンを形成している。

During the past decade, Tokushima University Hospital conducted 62 clinical trials. In the 10-year time frame, 62 clinical trials started and 24 clinical trials were completed, i.e. on average, 38.7% percent of trials that started reached the finish line to date. In the past 5 years, 30 clinical trials started and 19 clinical trials were completed. i.e. 63.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokushima University Hospital" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Pfizer" with 9 trials sponsored, "Boehringer Ingelheim" with 7 trials sponsored, "BioMarin Pharmaceutical" with 5 trials sponsored and "Janssen Research & Development, LLC" with 5 trials sponsored. Other sponsors include 33 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokushima University Hospital" #1 collaborator was "Astellas Pharma Inc" with 4 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Boehringer Ingelheim" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator and "Niigata University Medical & Dental Hospital" with 2 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "Tokushima University Hospital" are "Achondroplasia" (5 trials), "Idiopathic Pulmonary Fibrosis" (5 trials), "Lung Diseases, Interstitial" (3 trials), "Non-small Cell Lung Cancer" (3 trials) and "Prostate Cancer" (3 trials). Many other conditions were trialed in "Tokushima University Hospital" in a lesser frequency.

Most popular intervention types in "Tokushima University Hospital" are "Drug" (67 trials), "Procedure" (5 trials), "Other" (4 trials), "Biological" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (23 trials), "Atezolizumab" (5 trials), "Nintedanib" (5 trials), "Aflibercept" (3 trials) and "BMN 111" (3 trials). Other intervention names were less common.

The vast majority of trials in "Tokushima University Hospital" are 70 trials for "All" genders, 5 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Tokushima University Hospital". undefined are not yet recruiting, 13 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 35 completed trials in Tokushima University Hospital, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Tokushima University Hospital, 3 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 57 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".